Treatment
CS-121 clinical trials
We’re tracking 2 recruiting studies that include CS-121, each written for real people, not researchers, below.
Recruiting studies
- NCT07176923RecruitingEarly Phase 1
Gene editing for familial chylomicronemia syndrome (FCS)
This study tests a new gene-editing treatment called CS-121 for people with FCS whose triglycerides remain very high despite standard therapy. It aims to lower triglyceride levels by editing the APOC3 gene.
Hefei, AnhuiAges 18–55 - NCT07371767RecruitingEarly Phase 1
Gene editing for high triglycerides in kids with FCS
This trial tests a new gene-editing treatment (CS-121) for children and teens with a rare inherited condition called Familial Chylomicronemia Syndrome (FCS). It aims to lower very high triglyceride levels and reduce the risk of pancreatitis.
Shanghai, Shanghai MunicipalityAges 4–18
Common questions
- Are there clinical trials studying CS-121?
- Yes. Clin2 currently lists 2 recruiting studies that include CS-121, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CS-121 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CS-121 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CS-121 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.